Marché nord-américain de la gestion des maladies musculo-squelettiques (MSK) – Tendances et prévisions de l'industrie jusqu'en 2030

Analyse et perspectives du marché de la gestion des maladies musculo-squelettiques (MSK) en Amérique du Nord

La demande croissante de progrès technologiques dans le diagnostic des maladies musculo-squelettiques, la sensibilisation croissante aux maladies musculo-squelettiques, la prévalence croissante de la PR et l'augmentation des cas de fractures osseuses sont autant de facteurs qui devraient stimuler la croissance du marché.

Le marché nord-américain de la gestion des maladies musculo-squelettiques (MSK) devrait croître au cours de l'année de prévision en raison de l'augmentation du nombre d'acteurs sur le marché et de la disponibilité d'appareils de surveillance avancés. Parallèlement à cela, les fabricants sont engagés dans l'activité de développement pour lancer de nouveaux appareils et des produits efficaces et précis sur le marché. Le développement croissant dans le domaine des techniques de soins de santé avancées stimule encore davantage la croissance du marché. Cependant, des difficultés telles que les réglementations strictes pour la production et la commercialisation des produits devraient freiner la croissance du marché au cours de la période de prévision.

L'augmentation des dépenses de santé consacrées au développement et à l'avancement des technologies médicales devrait offrir des opportunités de croissance du marché. Cependant, le coût élevé des dispositifs de gestion des maladies devrait constituer un défi pour la croissance du marché. Diverses entreprises prennent des initiatives qui conduisent progressivement à la croissance du marché.

Data Bridge Market Research analyse que le marché nord-américain de la gestion des maladies musculo-squelettiques (MSK) devrait atteindre une valeur de 21 318,48 millions USD d'ici 2030, à un TCAC de 23,0 % au cours de la période de prévision 2023-2030.

Market Definition

Musculoskeletal (MSK) disease or impairments comprise more than 150 different diseases or conditions which internally affect the human system and are characterized by deficiencies in the muscles, bones, joints, and adjacent connective tissues, which lead to lifelong hindrances in functioning and participation. The conditions are characterized by pain, limited gait movement, and dexterity, thereby reducing people’s aptitude to work and participate in society.

The management of MSK diseases involves consultation with a physician, integrated with telemedicine, which is the use of digital biofeedback systems (DBSs), musculoskeletal-focused digital apps (MDAs), and therapies. Physical activity and weight management programs are also important self-management activities for persons with arthritis. Virtual therapy or remote consultation entails a holistic approach with the implementation of video conference and phone consultations in MSK practice.

North America Musculoskeletal (MSK) Disease Management Market Dynamics

This section deals with understanding the market drivers, opportunities, restraints, and challenges. All of this is discussed in detail below:     

Drivers

• Technological advances in the diagnosis of musculoskeletal disorders (MSDS)

Musculoskeletal disorders (MSDs) are injuries and disorders that affect the movement of the human body in the musculoskeletal (MSK) system, such as muscles, ligaments, nerves, tendons, cartilage, and discs. Some of the more common MSK conditions are myasthenia gravis, Osteoarthritis (OA), gout, Rheumatoid Arthritis (RA), back pain, osteoporosis, and Systemic Lupus Erythematosus (SLE). MSK pain has various causes. For example, muscle tissue can be damaged by wear and tear during daily activities. The strain on human body parts due to sprains, car accidents, falls, jerky movements, fractures, dislocations, and direct muscle blows also cause MSK pain.

For instance,

• In June 2018, Konica Minolta Healthcare Americas, Inc. launched the SONIMAGE MX1 portable ultrasound system developed for MSK and orthopedic practices, interventional guidelines, and ambulatory care centers. The SONIMAGE MX1 is built with the power and portability that doctors need to safely and effectively diagnose at the point of care. In March 2018, Philips presented a new 3-tesla MRI scanner called Ingenia Elition 3.0T at ECR 2018 in Vienna.

Thus, innovative steps and technological advancements by market players to improve the quality and efficiency of therapeutic research for MSDs are expected to drive market growth in the coming years.

• Rising awareness about musculoskeletal disorders (MSDS)

MSK diseases are associated with sports, occupational accidents, and aging-related dysfunctions. Some of the most common MSK conditions include back pain, RA, OA, osteoporosis, septic arthritis, gout, myasthenia gravis, SLE, and others. MSK disease management involves the diagnosis and treatment of all acute and chronic diseases that affect the MSK system, that is, muscles, bones, tendons, joints, and ligaments, as well as the treatment of non-surgical injuries of the MSK system.

According to reports published by the Bone and Joint Diseases Associations, the three most common MSK conditions are arthritis, back pain, and trauma.

Henceforth, the rising awareness about MSDs is positively associated with market growth in the coming years.

Restraint

• High cost of diagnosis and treatment of orthopedic diseases

Chronic orthopedic diseases such as arthritis and bursitis affect the MSK system- most often the bones or joints. They can cause pain and dysfunction, making normal daily activities difficult. These conditions are different from orthopedic injuries, such as a dislocated shoulder or broken bone, which are often caused by sudden trauma. Unlike accidental or traumatic orthopedic injuries, chronic conditions are usually progressive, starting slowly and worsening or developing over time. They may be genetic or age-related, or they may be caused by overuse.

Some orthopedic conditions are treatable, and some cannot be cured at this time but can be treated to reduce pain and improve quality of life. Accurate diagnosis and targeted treatment can help reduce problems even in progressive conditions without treatment. Treatment recommendations depend on the type and severity of your condition. Treatments range from RICE (Rest, Ice, Compression, and Elevation) to major surgery.

For instance,

• Full genome-genome comparisons
• Rapid assessment of polymorphic genetic variations
• Complete construction of orthologous and paralogous groups of genes
• Structure determination of large macromolecular assemblies/complexes
• Dynamical simulation of realistic oligomer systems

All these diagnostic, as well as therapeutic procedures, involve high costs. Thus, the high cost of diagnosis and treatment of orthopedic disease is expected to restrain the market growth.

Opportunity

• Strategic Initiatives by Market Players

The rise in musculoskeletal (MSK) diseases increases the need for strategic business ideas. It includes partnership, business expansion, collaboration, and other developments. In North America MSK disease management, many health agencies and market players entail initiatives that are designed to deliver returns on investment to the customers. The planned strategies allow the market players to align with the organization's functional activities to achieve set goals. It guides the company's discussions and decision-making in determining resource and budget requirements to accomplish objectives, thus increasing operational efficiency.

For instance -

• In March 2021, SpineZone declared an investment of USD 12.00 million in series a funding to integrate virtual and in-person (telemedicine) MSK care. The investment made is expected to expand the product and business footprint across North America and Europe with new funds.
• In September 2021, IncludeHealth launched the MSK operating system for virtual physical therapy. The MSK operating system provides an integrated virtual and in-person care telehealth experience. The launch was a result of the collaboration of IncludeHealth with Google and ProMedica Health Systems. The launch resulted in the expansion of the product portfolio and a rise in sales.

These strategic initiatives by the market players, including acquisition, conferences, and focused segment product launches, are helping them grow and improve the company's product portfolio, ultimately leading to more revenue generation. Hence, these strategic initiatives by the market players may be expected to as an opportunity that is expected to drive the market growth.

Challenge

• Challenges faced by physicians while treating athletes with musculoskeletal (MSK) diseases

Although primary prevention mainly involves coaches and trainers, secondary and tertiary prevention of sport-related injuries, the reduction of injuries as well as their consequences to allowing effective sport participation, are the main challenges for healthcare professionals who treat athletes suffering from MSK diseases. Several unmet needs are required to be addressed, such as heterogeneous epidemiological data reporting sport-related MSK injury.

Various challenges of implementing next-generation sequencing in the clinical laboratory are as follows-

• The challenge faced in improving the prevention and management of Rheumatic and Musculoskeletal Diseases (RMDs) is peripheral nerve repair which is a major challenge in clinical practice
• The special issue by the Italian Society for Unified and Interdisciplinary Management of Musculoskeletal Pain and Algodystrophy (Società Italiana per la Gestione Unificata e Interdisciplinare del Dolore muscolo-scheletrico e dell’Algodistrofia, SI-GUIDA) provided an overview of current epidemiological data, diagnostic challenges, and rationale of therapeutic strategies in the field of sport-related MSK diseases from the point of view of the three specialists most involved in the treatment of MSK pain, including the orthopedist, the rheumatologist, and the physiatrist.

MSK pain is a broad term for multiple conditions with different trajectories but collated together. They represent a substantial burden on physicians, patients (athletes), and the healthcare system. It is a challenging condition for both patients and physicians. Many adults have experienced one or more episodes of MSK pain at some time in their lives, regardless of age, gender, or economic status. In addition, the challenges faced by the physicians would result in less supply and distribution of digital (telehealth) products and less use of therapies. Therefore, the challenges faced by clinicians while treating athletes with MSK diseases are expected to challenge the market growth.

Recent Developments

• In January 2021, DarioHealth Corp. acquired AI-enabled MSK assessment company Physimax. The acquisition resulted in the addition of AI solutions and investments in DarioHealth Corp. MSK care portfolio.
• In January 2021, IncludeHealth formed a partnership with Google and ProMedica for the launch of the MSK operating system. The partnership and the product launch would propel the next generation of telemedicine and remote care. It is also expected to cause a rise in product revenue and expansion of business with existing customers.

North America Musculoskeletal (MSK) Disease Management Market Scope

North America musculoskeletal (MSK) disease management market is segmented into seven segments which are type, technology, integration type, modality, application, patient population, and end user. The growth amongst these segments will help you analyze meager growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Type

• Digital Biofeedback System
• Musculoskeletal-Focused Digital Apps (MDAS)
• Solutions
• Others

On the basis of type, the North America musculoskeletal (MSK) disease management market is segmented into digital biofeedback system, musculoskeletal-focused digital apps (MDAs), solutions, and others.

Technology

• Precision Motion Technology
• Computer Vision Technology
• Other Technologies

On the basis of technology, the North America musculoskeletal (MSK) disease management market is segmented into precision motion technology, computer vision technology, and other technologies.

Integration Type

• Phone
• Tablet
• Computer
• Others

On the basis of integration type, the North America musculoskeletal (MSK) disease management market is segmented into phone, tablet, computer, and others.

Modality

• Virtual Therapy
• In-Person Therapy
• Customized/ Personalized Therapy
• Others

On the basis of modality, the North America musculoskeletal (MSK) disease management market is segmented into virtual therapy, in-person therapy, customized/personalized therapy, and others.

Application

• Pre-Surgery Application
• Post-Surgery Application

On the basis of application, the North America musculoskeletal (MSK) disease management market is segmented into pre-surgery application and post-surgery application.

Patient Population

• Pediatrics
• Adults
• Geriatrics

On the basis of patient population, the North America musculoskeletal (MSK) disease management market is segmented into pediatrics, adults, and geriatrics.

End User

• Hospitals & Clinics
• Nursing Homes
• Health Centers
• Rehabilitation Centers
• Virtual/Home Health Care Settings
• Others

On the basis of end-user, the North America musculoskeletal (MSK) disease management market is segmented into hospitals & clinics, nursing homes, health centers, rehabilitation centers, virtual/home health care settings, and others.

North America Musculoskeletal (MSK) Disease Management Market Regional Analysis/Insights

North America musculoskeletal (MSK) disease management market is segmented into seven notable segments, which are type, technology, integration type, modality, application, patient population, and end user.

The countries covered in this market report are U.S., Canada, and Mexico.

The U.S. is expected to dominate the North America musculoskeletal (MSK) disease management market due to the rise in technological advancement in musculoskeletal (MSK) disease management products.

La section par pays du rapport fournit également des facteurs individuels ayant un impact sur le marché et des changements dans la réglementation du marché national qui ont un impact sur les tendances actuelles et futures du marché. Des points de données tels que les nouvelles ventes, les ventes de remplacement, la démographie du pays, les actes réglementaires et les tarifs douaniers d'import-export sont quelques-uns des principaux indicateurs utilisés pour prévoir le scénario du marché pour les différents pays. En outre, la présence et la disponibilité des marques régionales et les défis auxquels elles sont confrontées en raison de la concurrence importante ou rare des marques locales et nationales, ainsi que l'impact des canaux de vente sont pris en compte lors de l'analyse prévisionnelle des données nationales.

Analyse du paysage concurrentiel et des parts de marché de la gestion des maladies musculo-squelettiques (MSK) en Amérique du Nord

Le paysage concurrentiel du marché de la gestion des maladies musculo-squelettiques (MSK) en Amérique du Nord fournit des détails sur les concurrents. Les détails inclus sont la présentation de l'entreprise, les finances de l'entreprise, les revenus générés, le potentiel du marché, les investissements en R&D, les nouvelles initiatives du marché, les sites et installations de production, les forces et les faiblesses de l'entreprise, le lancement du produit, les approbations de produits, la largeur et l'étendue du produit, la domination des applications et la courbe de survie du type de produit. Les points de données ci-dessus fournis ne concernent que l'orientation de l'entreprise sur le marché.

Certains des principaux acteurs du marché opérant sur le marché nord-américain de la surveillance et des soins à distance des patients sont RecoveryOne, Kiio, Omada Health Inc., DarioHealth Corp., IncludeHealth, kaia health, IMC., Wellness Coaches USA, LLC, Sparta Science, Movement RX, Phzio, Airrosti Rehab Center, LLC, SimpleTherapy, Inc., Hinge Health, Inc., Sword Health, Inc., SPRITE HEALTH et Limber Health, Inc. entre autres.

SKU-69485